Your browser doesn't support javascript.
loading
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.
Hanna, Michael G; Badrising, Umesh A; Benveniste, Olivier; Lloyd, Thomas E; Needham, Merrilee; Chinoy, Hector; Aoki, Masashi; Machado, Pedro M; Liang, Christina; Reardon, Katrina A; de Visser, Marianne; Ascherman, Dana P; Barohn, Richard J; Dimachkie, Mazen M; Miller, James A L; Kissel, John T; Oskarsson, Björn; Joyce, Nanette C; Van den Bergh, Peter; Baets, Jonathan; De Bleecker, Jan L; Karam, Chafic; David, William S; Mirabella, Massimiliano; Nations, Sharon P; Jung, Hans H; Pegoraro, Elena; Maggi, Lorenzo; Rodolico, Carmelo; Filosto, Massimiliano; Shaibani, Aziz I; Sivakumar, Kumaraswamy; Goyal, Namita A; Mori-Yoshimura, Madoka; Yamashita, Satoshi; Suzuki, Naoki; Katsuno, Masahisa; Murata, Kenya; Nodera, Hiroyuki; Nishino, Ichizo; Romano, Carla D; Williams, Valerie S L; Vissing, John; Auberson, Lixin Zhang; Wu, Min; de Vera, Ana; Papanicolaou, Dimitris A; Amato, Anthony A.
Afiliación
  • Hanna MG; Medical Research Council (MRC) Centre for Neuromuscular Diseases, University College London (UCL) Institute of Neurology, London, UK. Electronic address: m.hanna@ucl.ac.uk.
  • Badrising UA; Department of Neurology, Leiden University Medical Center, Leiden, Netherlands.
  • Benveniste O; Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.
  • Lloyd TE; Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Needham M; Fiona Stanley Hospital, Institute for Immunology & Infectious Diseases Murdoch University and Notre Dame University, Perth, WA, Australia.
  • Chinoy H; National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
  • Aoki M; Department of Neurology, Tohoku University School of Medicine, Sendai, Japan.
  • Machado PM; Medical Research Council (MRC) Centre for Neuromuscular Diseases, University College London (UCL) Institute of Neurology, London, UK; Centre for Rheumatology, Division of Medicine, UCL, London, UK.
  • Liang C; Department of Neurology, Royal North Shore Hospital, Sydney, NSW, Australia.
  • Reardon KA; Calvary Health Care Bethlehem, Caulfield South, VIC, Australia.
  • de Visser M; Department of Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands.
  • Ascherman DP; Department of Medicine, University of Miami, Miami, FL, USA.
  • Barohn RJ; Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.
  • Dimachkie MM; Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.
  • Miller JAL; Department of Neurology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Kissel JT; Department of Neurology, Ohio State University Wexner Medical Center, Columbus, OH, USA.
  • Oskarsson B; UC Davis School of Medicine, Neuromuscular Research Center, Sacramento, CA, USA.
  • Joyce NC; UC Davis School of Medicine, Neuromuscular Research Center, Sacramento, CA, USA.
  • Van den Bergh P; Department of Neurology, University Hospital Saint-Luc, University of Louvain, Brussels, Belgium.
  • Baets J; Neuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, and the Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
  • De Bleecker JL; Department of Neurology, Ghent University Hospital, Ghent, Belgium.
  • Karam C; Department of Neurology, Oregon Health & Science University, Portland, OR, USA.
  • David WS; Department of Neurology, Massachusetts General Hospital, Neuromuscular Diagnostic Center and Electromyography Laboratory, Boston, MA, USA.
  • Mirabella M; Department of Neurology, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Universitá Cattolica del Sacro Cuore, Rome, Italy.
  • Nations SP; Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Jung HH; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
  • Pegoraro E; Department of Neurosciences, University of Padua School of Medicine, Padua, Italy.
  • Maggi L; Neuroimmunology and Neuromuscular Diseases Unit, Foundation IRCCS Neurological Institute Carlo Besta, Milan, Italy.
  • Rodolico C; Unit of Neurology and Neuromuscular Disorders, Azienda Ospedaliera Universitaria Policlinico G Martino, University of Messina, Messina, Italy.
  • Filosto M; Center for Neuromuscular Diseases, Unit of Neurology, Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy.
  • Shaibani AI; Nerve and Muscle Center of Texas, Houston, TX, USA.
  • Sivakumar K; Neuromuscular Research Center, Phoenix, AZ, USA.
  • Goyal NA; Department of Neurology, University of California Irvine, Amyotrophic Lateral Sclerosis & Neuromuscular Center, Orange, CA, USA.
  • Mori-Yoshimura M; Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
  • Yamashita S; Department of Neurology, Kumamoto University Hospital, Kumamoto, Japan.
  • Suzuki N; Department of Neurology, Tohoku University Hospital, Miyagi, Japan.
  • Katsuno M; Department of Neurology, Nagoya University Hospital, Aichi, Japan.
  • Murata K; Wakayama Medical University Hospital, Wakayama, Japan.
  • Nodera H; Tokushima University Hospital, Tokushima, Japan.
  • Nishino I; Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
  • Romano CD; RTI Health Solutions, Research Triangle Park, NC, USA.
  • Williams VSL; RTI Health Solutions, Research Triangle Park, NC, USA.
  • Vissing J; Copenhagen Neuromuscular Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Auberson LZ; Novartis Pharma, Basel, Switzerland.
  • Wu M; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • de Vera A; Novartis Pharma, Basel, Switzerland.
  • Papanicolaou DA; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • Amato AA; Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Lancet Neurol ; 18(9): 834-844, 2019 09.
Article en En | MEDLINE | ID: mdl-31397289
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Miositis por Cuerpos de Inclusión / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Neurol Asunto de la revista: NEUROLOGIA Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Miositis por Cuerpos de Inclusión / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Neurol Asunto de la revista: NEUROLOGIA Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido